Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Capecitabine in HR+/HER2- Breast Cancer
NCT04274933Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of venetoclax in breast cancer (2 arms), sponsored by AbbVie Inc. Primary endpoints: Number of participants with Dose Limiting Toxicities at 21 days, Maximum observed plasma concentration of venetoclax at 9 days and 1 more. Started May 2020; status: terminated.
02
Drugs
venetoclax
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04274933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274933.